Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

1
State Street Corporation (STT) CEO Jay Hooley on Q2 2018 Results - Earnings Call Transcript

18h seekingalpha
Good morning, and welcome to State Street Corporation's Second Quarter of 2018 Earnings Conference Call and Webcast. Today's discussion is being broadcast live on State Street's website at investors.statestreet.com.
STT STT.PRC STT.PRE STT.PRD MS.PRE STT.PRG MS.PRF MS.PRG MS.PRA MS.PRI MS.PRK 3772 MS

3
Sluggish Results And Guidance Renew Questions About BB&T's Self-Improvement

19h seekingalpha
Weak growth and weaker guidance from BB&T leave a sour taste, and the market is worried BB&T will divert capital from buybacks toward M&A.
BBT STT STT.PRC CMA STT.PRE STT.PRD STT.PRG

1
State Street Stock Slides Lower on Charles River Deal

20h investorplace
The deal will have State Street spending a total of $2.6 billion to acquire the provider of investment management front office tools and solutions. STT also notes that the deal will be fully funded with cash.
STT STT.PRC STT.PRE STT.PRD STT.PRG

1
Friday’s Biggest Winners and Losers in the S&P 500

21h 247wallst
July 20, 2018: The S&P 500 closed flat at 2,801.92. The DJIA closed flat at 25,057.92. Separately, the Nasdaq was flat at 7,820.20.
STT CTAS STT.PRC STT.PRE STT.PRD STT.PRG

1
State Street falls after halting buyback to complete merger

23h cnbc
State Street shares dropped 7 percent on Friday, on track for their worst day in two years, after the bank announced it will suspend a share buyback to acquire Charles River Development.
STT STT.PRC STT.PRE STT.PRD STT.PRG

1
State Street Corporation 2018 Q2 - Results - Earnings Call Slides

23h seekingalpha
The following slide deck was published by State Street Corporation in conjunction with their 2018 Q2 earnings call.
STT STT.PRC STT.PRE STT.PRD STT.PRG

1
S&P flat as gains in Microsoft offset tariff fears

2018-07-20 theedgemarkets
NEW YORK (July 20): The S&P 500 was trading flat on Friday as Microsoft's robust results helped offset escalating tariff worries after President Donald Trump said he was ready to impose levies on US$500 billion worth of goods from China.
SCHW.PRBCL STT STT.PRC STT.PRE STT.PRD STT.PRG

19
Q2 Earnings Point Markets Forward: MSFT, GE, VFC & More

2018-07-20 zacks
Friday, July 20, 2018 Q2 results continue to heat up at the end of this first full week of earnings season, coming off yesterday afternoon’s fiscal Q4 results from Microsoft (MSFT - Free Report) beating on both top and bottom lines. The software giant’s $1.13 per share topped the Zacks consensus by 6 cents, and up 6.6% from the previous year’s quarter. Sales of $30.1 billion outperformed the $29.2 billion expected.
STT SLB GEC GE STT.PRC STT.PRE STT.PRD STT.PRG GNE MSFT SLB

19
Earnings Data Deluge

2018-07-20 zacks
Q2 results continue to heat up at the end of this first full week of earnings season, coming off yesterday afternoon’s fiscal Q4 results from Microsoft (MSFT - Free Report) beating on both top and bottom lines. The software giant’s $1.13 per share topped the Zacks consensus by 6 cents, and up 6.6% from the previous year’s quarter. Sales of $30.1 billion outperformed the $29.2 billion expected. Results were bolstered by strength in its Cloud business, up 53% year over year.
STT SLB GEC GE STT.PRC STT.PRE STT.PRD STT.PRG GNE MSFT SLB

4
State Street (STT) Beats on Q2 Earnings, to Acquire CRD

2018-07-20 zacks
State Street’s (STT - Free Report) second-quarter 2018 adjusted earnings of $2.05 per share outpaced the Zacks Consensus Estimate of $2.01. Results excluded $77 million or 17 cents per share of repositioning charge related to organizational realignment. State Street’s shares lost more than 5% in pre-market trading. Suspension of share buybacks till the end of this year due to the announcement of deal to acquire Charles River Development (“CRD”) is perhaps the primary reason.
BBT STT STT.PRC CMA STT.PRE STT.PRD STT.PRG KEY

1
S&P flat as gains in Microsoft offset tariff fears

2018-07-20 malaymail
NEW YORK, July 20 — The S&P 500 was trading flat today as Microsoft’s robust results helped offset escalating tariff worries after President Donald Trump said he was ready to impose levies on US$500 billion (RM2 trillion) worth of goods from China.
SCHW.PRBCL STT STT.PRC STT.PRE STT.PRD STT.PRG

16
Markets Right Now: US stocks open mostly lower

2018-07-20 nzherald.co.nz
Stocks are opening mostly lower on Wall Street as investors react to some disappointing earnings reports.
STT GEC GE NDAQ STT.PRC STT.PRE STT.PRD STT.PRG GNE

1
State Street (STT) Beats on Q2 Earnings, Revenue Rise Y/Y

2018-07-20 zacks
Have you been eager to see how State Street Corporation (STT - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this MA -based popular company’s earnings release this morning: An Earnings Beat State Street came out with adjusted earnings of $2.05 per share, which beat the Zacks Consensus Estimate of $2.01. Rise in revenues primarily supported the results.
CFIN STT RF.PRB RF.PRA STT.PRC KDP CIWV STT.PRE STT.PRD STT.PRG RF

1
U.S. custodian bank State Street to buy Charles River for $2.6 bln

2018-07-20 reuters
(Reuters) - U.S. custodian bank State Street Corp (STT.N) said on Friday it would buy Charles River Development, a privately held investment management firm, for $2.6 billion in cash.
STT STT.PRC STT.PRE STT.PRD STT.PRG

1
EDIV Vs DVYE: Which Is The Best Way To Play Emerging Markets?

2018-07-20 seekingalpha
EDIV and DVYE are the two most popular ETFs focused on dividend-paying stocks in emerging markets.
STT EDIV LUKZY STT.PRC OGZPY STT.PRE STT.PRD OGZRY STT.PRG INDA DVYE LUKOY LUKFY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...